Histone Deacetylase Inhibitor Therapy in Epithelial Ovarian Cancer


Since epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in ovarian cancers, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. In this review, we discuss the biologic and therapeutic effects of HDAC inhibitors… (More)
DOI: 10.1155/2010/458431


2 Figures and Tables